Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: paratekpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2023 | $7.00 → $5.00 | Buy | Jefferies |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 2/10/2022 | $11.00 | Buy → Strong Buy | WBB Securities |
| 11/9/2021 | $28.00 → $27.00 | Buy | HC Wainwright & Co. |
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-12) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209816, Application Classification: Labeling
Jefferies resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $5.00 from $7.00 previously
BTIG Research resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $24.00
WBB Securities upgraded Paratek Pharmaceuticals from Buy to Strong Buy and set a new price target of $11.00
HC Wainwright & Co. reiterated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $27.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $28.00 from $22.00 previously
WBB Securities upgraded Paratek Pharmaceuticals from Speculative Buy to Buy and set a new price target of $10.00
Jefferies Financial Group initiated coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $15.00
SVB Leerink resumed coverage of Paratek Pharmaceuticals with a rating of Buy and set a new price target of $14.00
Jefferies initiated coverage of Paratek Pharma with a rating of Buy and set a new price target of $15.00
HC Wainwright resumed coverage of Paratek Pharmaceuticals with a rating of Buy